Summary Anika Therapeutics, Inc. (Anika) is a medical technology company which develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products include viscosupplementation and regenerative orthopedics products, advanced wound care devices, anti-adhesion gels, viscoelastic ophthalmic products, dental bone grafting adjuncts and joint dysfunction management fluids for horses. Its products are made from hyaluronic acid (HA) based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Anika has research and manufacturing facilities in Bedford, Massachusetts. Anika is headquartered in Massachusetts, the US. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Anika Therapeutics, Inc. - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Anika Therapeutics, Inc. Company Snapshot 6 Anika Therapeutics, Inc. Company Overview 6 Anika Therapeutics, Inc. Pipeline Products and Clinical Trials Overview 7 Anika Therapeutics, Inc. - Pipeline Analysis Overview 10 Business Description 10 Key Facts 10 Anika Therapeutics, Inc. - Major Products and Services 12 Anika Therapeutics, Inc. Pipeline Products by Development Stage 14 Anika Therapeutics, Inc. Clinical Trials by Trial Status 16 Anika Therapeutics, Inc. Pipeline Products Overview 18 Cingal 18 Cingal Product Overview 18 Cronofill 19 Cronofill Product Overview 19 Hemostatic Patch 20 Hemostatic Patch Product Overview 20 HYAFF Barrier Film 21 HYAFF Barrier Film Product Overview 21 HYAFF Gel 22 HYAFF Gel Product Overview 22 HYAFF Mesh 23 HYAFF Mesh Product Overview 23 HYAFF/ACP Spray - Adhesion 24 HYAFF/ACP Spray - Adhesion Product Overview 24 Hyalobone 25 Hyalobone Product Overview 25 Hyalofast 26 Hyalofast Product Overview 26 Hyalofast Clinical Trial 27 Hyaloglide 28 Hyaloglide Product Overview 28 Hyalograft C Autograft 29 Hyalograft C Autograft Product Overview 29 Hyalonect 30 Hyalonect Product Overview 30 INCERT-S 31 INCERT-S Product Overview 31 MONOVISC - Hip 32 MONOVISC - Hip Product Overview 32 MONOVISC - Hip Clinical Trial 33 Next Generation ELEVESS Dermal Filler 34 Next Generation ELEVESS Dermal Filler Product Overview 34 Anika Therapeutics, Inc. - Key Competitors 35 Anika Therapeutics, Inc. - Key Employees 36 Anika Therapeutics, Inc. - Key Employee Biographies 37 Anika Therapeutics, Inc. - Locations And Subsidiaries 38 Head Office 38 Other Locations & Subsidiaries 38 Recent Developments 39 Anika Therapeutics, Inc., Recent Developments 39 Jun 01, 2016: Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis 39 May 19, 2016: Pendopharm Announces Canadian Launch Of Cingal In Partnership With Anika Therapeutics 39 Apr 27, 2016: Anika Reports First Quarter 2016 Financial Results 40 Apr 04, 2016: Anika Appoints New Chief Medical Officer and Chief Operations Officer 40 Mar 28, 2016: Anika Therapeutics Wins CE Mark Approval For Cingal For The Treatment Of Pain Associated With Osteoarthritis Of The Knee 41 Feb 24, 2016: Anika Therapeutics Delivers Strong Performance with Record Product Revenue for the Fourth Quarter and Full Year 2015 42 Dec 29, 2015: Anika Therapeutics Announces First Patient Enrolled in FastTRACK Phase III HYALOFAST Study 43 Dec 09, 2015: Anika Therapeutics Announces Decision to Proceed with CINGAL Premarket Review Through FDA's Center for Drug Evaluation and Research 43 Nov 03, 2015: Anika Therapeutics Announces Health Canada Approval of CINGAL for the Treatment of Pain Associated with Osteoarthritis of the Knee 44 Oct 29, 2015: Anika Appoints Richard Hague to Role of Chief Commercial Officer 44 Appendix 45 Methodology 45 About GlobalData 45 Contact Us 45 Disclaimer 45
List of Tables
Anika Therapeutics, Inc. Pipeline Products and Clinical Trials Overview 7 Anika Therapeutics, Inc. Pipeline Products by Equipment Type 7 Anika Therapeutics, Inc. Pipeline Products by Indication 9 Anika Therapeutics, Inc. Clinical Trials by Trial Status 9 Anika Therapeutics, Inc., Key Facts 11 Anika Therapeutics, Inc., Major Products and Services 12 Anika Therapeutics, Inc. Number of Pipeline Products by Development Stage 14 Anika Therapeutics, Inc. Pipeline Products Summary by Development Stage 15 Anika Therapeutics, Inc. Clinical Trials by Trial Status 16 Anika Therapeutics, Inc. Clinical Trials Summary 17 Cingal - Product Status 18 Cingal - Product Description 18 Cronofill - Product Status 19 Cronofill - Product Description 19 Hemostatic Patch - Product Status 20 Hemostatic Patch - Product Description 20 HYAFF Barrier Film - Product Status 21 HYAFF Barrier Film - Product Description 21 HYAFF Gel - Product Status 22 HYAFF Gel - Product Description 22 HYAFF Mesh - Product Status 23 HYAFF Mesh - Product Description 23 HYAFF/ACP Spray - Adhesion - Product Status 24 HYAFF/ACP Spray - Adhesion - Product Description 24 Hyalobone - Product Status 25 Hyalobone - Product Description 25 Hyalofast - Product Status 26 Hyalofast - Product Description 26 Hyalofast - HYALOFAST FastTRACK Phase III Clinical Study 27 Hyaloglide - Product Status 28 Hyaloglide - Product Description 28 Hyalograft C Autograft - Product Status 29 Hyalograft C Autograft - Product Description 29 Hyalonect - Product Status 30 Hyalonect - Product Description 30 INCERT-S - Product Status 31 INCERT-S - Product Description 31 MONOVISC - Hip - Product Status 32 MONOVISC - Hip - Product Description 32 MONOVISC - Hip - Investigational Device Exemption (IDE) Phase III Study of MONOVISC to Treat Pain Caused by Osteoarthritis of the Hip 33 Next Generation ELEVESS Dermal Filler - Product Status 34 Next Generation ELEVESS Dermal Filler - Product Description 34 Anika Therapeutics, Inc., Key Employees 36 Anika Therapeutics, Inc., Key Employee Biographies 37 Anika Therapeutics, Inc., Subsidiaries 38
List of Figures
Anika Therapeutics, Inc. Pipeline Products by Equipment Type 8 Anika Therapeutics, Inc. Pipeline Products by Development Stage 14 Anika Therapeutics, Inc. Clinical Trials by Trial Status 16
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.